TG Therapeutics, Inc.
$36.96
▼
-0.15%
2026-04-21 09:48:00
www.tgtherapeutics.com
NCM: TGTX
Explore TG Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.64 B
Current Price
$36.96
52W High / Low
$46.48 / $25.28
Stock P/E
12.6
Book Value
$4.52
Dividend Yield
—
ROCE
13.56%
ROE
1.03%
Face Value
—
EPS
$2.77
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
399
Beta
1.75
Debt / Equity
39.26
Current Ratio
4.1
Quick Ratio
3.29
Forward P/E
13.7
Price / Sales
8.74
Enterprise Value
$5.09 B
EV / EBITDA
41.28
EV / Revenue
8.27
Rating
Buy
Target Price
$44.43
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Soleno Therapeutics, Inc. | $52.67 | 130.16 | $2.72 B | — | 2.98% | 6.01% | $90.32 / $29.43 | $8.61 |
| 2. | BridgeBio Pharma, Inc. | $74.02 | — | $14.41 B | — | -77.47% | 40.79% | $84.94 / $31.77 | $-10.71 |
| 3. | Filana Therapeutics, Inc. | $1.75 | — | $84.54 M | — | -128.99% | -82.66% | $2.27 / $1.53 | $1.54 |
| 4. | ImmunityBio, Inc. | $8.01 | — | $8.28 B | — | -58.17% | 71.02% | $12.43 / $1.83 | $-0.49 |
| 5. | Lexaria Bioscience Corp. | $0.99 | — | $25.53 M | — | -443.04% | -1.55% | $1.69 / $0.46 | $0.22 |
| 6. | Cartesian Therapeutics, Inc. | $6.94 | — | $183.97 M | — | -30.8% | 195.88% | $15.57 / $5.6 | $-4.85 |
| 7. | Polyrizon Ltd. | $11.64 | — | $20.34 M | — | -27.56% | -25.38% | $2,235 / $2.88 | $13.05 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 192.57 M | 161.71 M | 141.15 M | 120.86 M | 108.19 M |
| Operating Profit | 50.49 M | 29.36 M | 34.84 M | 8.62 M | 29.95 M |
| Net Profit | 23.04 M | 390.89 M | 28.19 M | 5.06 M | 23.33 M |
| EPS in Rs | 0.14 | 2.45 | 0.18 | 0.03 | 0.15 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 616.29 M | 329 M | 233.66 M | 2.79 M |
| Operating Profit | 123.32 M | 41.93 M | 20.63 M | -218.32 M |
| Net Profit | 447.18 M | 23.38 M | 12.67 M | -223.81 M |
| EPS in Rs | 2.8 | 0.15 | 0.08 | -1.4 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.06 B | 577.69 M | 329.59 M | 193.57 M |
| Total Liabilities | 415.23 M | 355.33 M | 169.09 M | 134.99 M |
| Equity | 648.02 M | 222.36 M | 160.5 M | 58.59 M |
| Current Assets | 630.76 M | 566.36 M | 317.94 M | 168.27 M |
| Current Liabilities | 153.76 M | 90.68 M | 53.72 M | 53.2 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -24.77 M | -40.52 M | -31.41 M | -176.17 M |
| Investing CF | 13.8 M | -1.04 M | -50.65 M | -20.01 M |
| Financing CF | -89.73 M | 128.53 M | 72.7 M | -0.39 M |
| Free CF | -24.99 M | -40.56 M | -31.41 M | -176.18 M |
| Capex | -0.21 M | -0.04 M | — | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 40.8% | 8290.02% | — | — |
| Earnings Growth % | 84.52% | 105.66% | — | — |
| Profit Margin % | 7.11% | 5.42% | -8036.34% | — |
| Operating Margin % | 12.74% | 8.83% | -7838.99% | — |
| Gross Margin % | 88.3% | 93.95% | 90.48% | — |
| EBITDA Margin % | 15.17% | 11.17% | -7651.92% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.